MedTrace Logo

BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam

NCT01017666 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2023-08-23

No results posted yet for this study

Summary

The purpose of this study is to understand whether BIIB014 has potential to affect how certain drugs are broken down by the body.

Conditions

  • Healthy

Interventions

DRUG

BIIB014

BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d

DRUG

Placebo

Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-01
Primary Completion
2010-06-02
Completion
2010-06-02

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01017666 on ClinicalTrials.gov